Giri Dinesh, Patil Prashant, Blair Joanne, Dharmaraj Poonam, Ramakrishnan Renuka, Das Urmi, Didi Mohammed, Senniappan Senthil
Department of Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, United Kingdom.
Int J Endocrinol Metab. 2017 Mar 7;15(2):e42311. doi: 10.5812/ijem.42311. eCollection 2017 Apr.
Constitutional delay of growth and puberty (CDGP) can cause significant psychological distress in adolescent boys. Although testosterone usage in this group has not been shown to affect the final adult height, the effect on the first year height velocity has not been widely reported.
The aim is to determine whether testosterone treatment improves the first year height velocity in boys with CDGP when compared to boys with CDGP who go through puberty spontaneously.
Retrospective data from 23 adolescent boys with CDGP was analysed. Ten out of 23 boys (43%) received testosterone injection (testosterone enanthate, 125 mg), once every 6 weeks for 3 doses in total. Both the groups (treated and untreated) had their height, bone age and testicular volume measured at the baseline, The height velocity and final predicted adult height were compared at the end of one year between both the groups.
In the testosterone-untreated group, the mean (± SD) chronological age, bone age, height standard deviation scores (SDS) and testicular volume were 14.3 years (± 0.3),12.1 years (± 1.6), -1.9 (± 0.8) and 4.7 mL (± 1.1) respectively. Within the testosterone-treated group the mean (± SD) chronological age, bone age, height SDS and testicular volume at presentation were 14.4 years (± 0.4), 11 years (± 1.6), -2.1 SD(± 0.6) and 4.5 mL (± 1.2) respectively. The mean age of treatment with testosterone was 14.4 years (± 0.44). The mean height velocity one year after treatment was 8.4 cm/year (± 1.7) in the testosterone treated group when compared to 6.1 cm/year (± 2.1) in the patients who did not receive treatment (P = 0.01). There was no significant difference in the final predicted height between the 2 groups (P = 0.15).
Testosterone therapy improves the first year height velocity in boys with CDGP, without influencing their final predicted height.
体质性生长和青春期延迟(CDGP)可给青春期男孩带来严重的心理困扰。虽然该群体使用睾酮尚未被证明会影响最终成年身高,但对第一年身高增长速度的影响尚未有广泛报道。
旨在确定与自然进入青春期的CDGP男孩相比,睾酮治疗是否能提高CDGP男孩第一年的身高增长速度。
分析了23例青春期CDGP男孩的回顾性数据。23名男孩中有10名(43%)接受了睾酮注射(庚酸睾酮,125毫克),每6周注射一次,共注射3剂。两组(治疗组和未治疗组)在基线时均测量了身高、骨龄和睾丸体积。比较两组在一年后身高增长速度和最终预测成年身高。
在未接受睾酮治疗的组中,平均(±标准差)实足年龄、骨龄、身高标准差评分(SDS)和睾丸体积分别为14.3岁(±0.3)、12.1岁(±1.6)、-1.9(±0.8)和4.7毫升(±1.1)。在接受睾酮治疗的组中,就诊时的平均(±标准差)实足年龄、骨龄、身高SDS和睾丸体积分别为14.4岁(±0.4)、11岁(±1.6)、-2.1标准差(±0.6)和4.5毫升(±1.2)。接受睾酮治疗的平均年龄为14.4岁(±0.44)。与未接受治疗的患者(6.1厘米/年±2.1)相比,接受睾酮治疗组治疗一年后的平均身高增长速度为8.4厘米/年(±1.7)(P = 0.01)。两组之间最终预测身高无显著差异(P = 0.15)。
睾酮治疗可提高CDGP男孩第一年的身高增长速度,而不影响其最终预测身高。